Product Information
REXULTI 0.25 MG TABLET is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $49.5228 per EA under NDC 59148003513. Its NADAC has been published 423 times since May 23, 2018.
Strength
.25 mg/1
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148003513
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
BREXPIPRAZOLEApproval Type
New Drug (NDA)
FDA Application
NDA205422On Market Since
7/10/2015
Pharmacological Classes
Price Statistics
The NADAC for REXULTI 0.25 MG TABLET has been published 423 times since May 23, 2018, and over the history we have for it it has risen 40.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $49.5228 per EA |
|---|---|
| All-time high | $49.5463 (Jun 10, 2026) |
| All-time low | $35.3413 (May 23, 2018) |
| 52-week high | $49.5463 |
| 52-week low | $48.1570 |
| Median price | $42.6453 |
| Average price | $42.2607 |
| Largest weekly change | +7.0% (Jan 20, 2021) |
| Weeks tracked | 423 |
| Tracking since | May 23, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the brexpiprazole market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of REXULTI 0.25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for REXULTI 0.25 MG TABLET, manufactured by Otsuka America Pharmaceutical Inc., is $49.5228 per EA (NDC 59148003513), effective Jun 24, 2026.
How has the price of REXULTI 0.25 MG TABLET changed over time?
Over the history we have for it, the NADAC for REXULTI 0.25 MG TABLET has risen 40.1%. It has been tracked across 423 weekly CMS publications since May 23, 2018.
What are the highest and lowest recorded NADAC prices for REXULTI 0.25 MG TABLET?
Since May 23, 2018, the NADAC for REXULTI 0.25 MG TABLET has ranged from a low of $35.3413 (May 23, 2018) to a high of $49.5463 (Jun 10, 2026), with a median of $42.6453 per EA.
Are there cheaper alternatives to REXULTI 0.25 MG TABLET?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of REXULTI 0.25 MG TABLET, so no direct lower-cost alternative is listed.
Who manufactures REXULTI 0.25 MG TABLET?
REXULTI 0.25 MG TABLET (NDC 59148003513) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification